In trials involving patients with advanced cancers,<unk>  exhibited linear pharmacokinetics across doses ranging from 1.0 to 24.9 mg/m2 when administered intravenously over four hours. Age, race, sex, mild-to-severe renal impairment, and mild-to-moderate hepatic impairment had no effect on<unk>  pharmacokinetics. No accumulation of plasma concentration was observed after repeated dosing.
Romidepsin
Lorcaserin
Palonosetron
Acetryptine
Bromopride
Cyfluthrin
Coralmyn
Tavilermide